Salvage Treatment With Lenalidomide and Dexamethaosne(LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL).
Phase of Trial: Phase II
Latest Information Update: 20 Aug 2016
At a glance
- Drugs Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Mantle-cell lymphoma
- Focus Biomarker; Therapeutic Use
- 22 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 22 Nov 2008 New trial record.